RecruitingPhase 4NCT06411665

Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting

Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting in Laparoscopic Colorectal Surgery: A Randomized Trial


Sponsor

Peking University First Hospital

Enrollment

252 participants

Start Date

Jul 2, 2024

Study Type

INTERVENTIONAL

Summary

Postoperative nausea and vomiting (PONV) is common after surgery and impede rapid recovery after surgery. Patients who undergo laparoscopic colorectal surgery are more likely to develop PONV due to the pneumoperitoneum, interruption of gastrointestinal system, delay of oral feeding, and nasogastric catheterization, as well as postoperative opioid analgesic requirement to control acute pain. Oliceridine is a novel selective μ-opioid agonist. It stimulates G protein signalling but is markedly less potent than morphine for β-arrestin recruitment; the latter contributes to opioid-related adverse events including PONV. It is postulated that G protein-biased agonists may deliver effective analgesia with fewer opioid-related adverse events. This randomized trial aimed to investigate whether oliceridine for patient-controlled analgesia can decrease the incidence of PONV in patients recovering from laparoscopic colorectal surgery.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

  • Aged between 18 and 80 years;
  • Scheduled to undergo elective laparoscopic colorectal surgery;
  • Required patient-controlled intravenous analgesia.

Exclusion Criteria4

  • Pregnancy.
  • Severe heart dysfunction (New York Heart Association functional classification 4), hepatic insufficiency (Child-Pugh grade C), renal insufficiency (serum creatinine of 442 μmol/L or above, or requirement of renal replacement therapy), or Amercian Society of Anesthesiologists classification IV or above.
  • Unable to complete preoperative assessment due to severe dementia or language barrier.
  • Other conditions that are considered unsuitable for study participation.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOliceridine

Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.

DRUGMorphine

Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.


Locations(1)

Dong-Xin Wang

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06411665